Mediti Pharma is a project focused company created to develop a single asset, MP-101. The project is fully financed through a Phase 2a study by TVM Life Science Ventures VII. The company will be managing the trial under a Canadian CTA and US IND.
The company is fortunate to have Dr. Serge Gauthier C.M., MD, FRCPC, Director of the Alzheimer’s Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging as Head of the Scientific Advisory Committee.
CEO Dr. Ivan Shaw, formerly with Merck Frosst, Aptalis and Actavis, is based in Montreal and brings a deep expertise in the neurosciences and drug development to the team.